Investigation of the Therapeutic Effects of Chloroquine in Adriamycin-Induced Hepatotoxicity

Basit Öğe Kaydı
dc.authorid0000-0002-0917-0378
dc.contributor.authorAkin, Ali Tuğrul
dc.contributor.authorKaymak, Emin
dc.contributor.authorÖztürk, Emel
dc.contributor.authorKarabulut, Derya
dc.contributor.authorKuloğlu, Nurhan
dc.contributor.authorCeylan, Tayfun
dc.contributor.authorToluk, Ayşe
dc.date.accessioned2021-03-10T11:20:25Z
dc.date.available2021-03-10T11:20:25Z
dc.date.issued2021en_US
dc.departmentKapadokya Üniversitesi, Kapadokya Meslek Yüksekokulu, Patoloji Laboratuvar Teknikleri Bölümü
dc.descriptionTARAMAWOS
dc.description.abstractThe aim of this study is to investigate the therapeutic effects of Chloroquine (CLQ) against Adriamycin (ADR) induced hepatotoxicity. ADR is a chemotherapeutic agent used in the treatment of many cancer types, but it causes hepatotoxicity. CLQ is used as an anti-inflammatory drug in the treatment of malaria, rheumatoid arthritis, and pneumonia caused by Covid-19. Rats were divided into four groups: Control group, ADR group (2 mg/kg Adriamycin, one in three days for 30 days, i.p.), CLQ group (50 mg/kg Chloroquine, per day for 30 days, i.p.), ADR+CLQ (2 mg/kg Adriamycin, one in three days for 30 days, i.p. and 50 mg/kg Chloroquine, per day for 30 days, i.p.). Animals were sacrificed, and liver tissues were extracted for further examinations. Histopathological changes in liver tissues were scored and IL-17 immunostaining was performed to determine the expression levels among experimental groups. Bodyweights in the ADR group decreased significantly compared to the Control group and CLQ group. Furthermore, bodyweight in ADR+CLQ group was significantly higher compared to ADR group. The histopathological score was significantly higher in ADR group when compared to Control and CLQ group while CLQ administrations reduced the damage induced by ADR in the ADR+CLQ group. IL-17 immunoreactivity was considerably increased in the ADR group. On the other hand, IL-17 expressions of ADR+CLQ were substantially less compared to ADR group. We suggest that CLQ can be used as a therapeutic agent to reduce the detrimental effects of ADR, thanks to its anti-inflammatory properties.
dc.identifier.citationAkin, A. T., Kaymak, E., Öztürk, E., Karabulut, D., Kuloğlu, N., Ceylan, T., & Toluk, A. (2021). Investigation of the Therapeutic Effects of Chloroquine in Adriamycin-Induced Hepatotoxicity. The EuroBiotech Journal, 5(1), 8-14.
dc.identifier.endpage14en_US
dc.identifier.issue1en_US
dc.identifier.startpage8en_US
dc.identifier.urihttps://doi.org/10.2478/ebtj-2021-0003
dc.identifier.urihttps://hdl.handle.net/20.500.12695/992
dc.identifier.volume5en_US
dc.identifier.wosWOS:000613126700004
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Sceince
dc.institutionauthorCeylan, Tayfun
dc.language.isoen
dc.publisherSciendo
dc.relation.ispartofThe EuroBiotech Journal
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAdriamycin
dc.subjectChloroquine
dc.subjectIL-17
dc.subjectLiver damage
dc.titleInvestigation of the Therapeutic Effects of Chloroquine in Adriamycin-Induced Hepatotoxicity
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Investigation of the Therapeutic Effects of Chloroquine in Adriamycin-Induced Hepatotoxicity.pdf
Boyut:
947.15 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale / Article
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

PLT - Makale Koleksiyonu